Willog is a Seoul-based AIoT supply chain company that turns invisible logistics events into data. Its patented sensor devices track temperature, shock, humidity and location across warehouse, road, ocean and air, feeding an AI-powered Control Tower that gives shippers of pharmaceuticals, semiconductors, chemicals and food real-time visibility, diagnostics and risk prediction. Founded in 2021, Willog serves 200+ global enterprise customers and reached a Series B-2 round in under five years.
Dynavax Technologies is an Emeryville, California biopharmaceutical company built around CpG 1018, a proprietary vaccine adjuvant that sharpens the immune system's response. Its flagship product, HEPLISAV-B, is the first and only two-dose adult hepatitis B vaccine approved in the U.S. and Europe, and had grown to roughly 44% U.S. market share by the end of 2024. Beyond hepatitis B, Dynavax licenses CpG 1018 to other vaccine developers - most visibly as an ingredient in several COVID-19 vaccines - and has advanced its own pipeline in shingles, plague, pandemic influenza, and Lyme disease. In December 2025 Sanofi agreed to acquire Dynavax for about $2.2 billion; the deal closed in February 2026.

J. Robert Coleman, PhD, MBA, is Chairman and CEO of HERVolution Therapeutics, a Copenhagen-based biotech developing immunotherapies that target human endogenous retroviruses (HERVs) - the ancient viral DNA lodged in the dark genome that reawakens in cancer, aging, and neurodegeneration. A trained virologist, he co-founded Codagenix, where he built a synthetic-biology vaccine platform into a clinical-stage pipeline and raised nearly half a billion dollars before pivoting to HERVs in late 2023.
The Biotechnology Innovation Organization (BIO) is the world's largest trade association for the biotech industry, representing more than 1,000 companies, research institutions and state and regional bio centers across the United States and 30-plus countries. Founded in 1993 and headquartered in Washington, D.C., BIO lobbies on drug pricing, intellectual property, regulation and biosecurity, and runs the BIO International Convention - the industry's flagship annual dealmaking and networking event. Led since 2024 by President and CEO John F. Crowley, a rare-disease entrepreneur whose own children have Pompe disease, BIO's stated mission is to advance a 'bio revolution' that cures patients, protects the climate and nourishes humanity.
Dr. Dino Dina is a Genoa-born physician-scientist who spent 15 years building Dynavax Technologies as its President and CEO, shepherding the company through the long road toward HEPLISAV-B, a two-dose hepatitis B vaccine whose CpG 1018 adjuvant technology later became a cornerstone of global COVID-19 vaccine programs. Before Dynavax, he built the Vaccine Group at Chiron Corporation and led Chiron Vaccines to the first-ever approval of an adjuvanted influenza vaccine in Italy. Since retiring in 2013, he has poured equal scientific rigor into his Cimarossa estate on Howell Mountain, Napa Valley - 60 mountain acres of vines and 1,200 olive trees named for the Italian phrase meaning 'red hilltop.'
Ryan Spencer is the CEO of Dynavax Technologies, the Emeryville biotech behind HEPLISAV-B and the CpG 1018 adjuvant. He joined as an interim controller in 2005, climbed for fourteen years through finance, IR, and commercial roles, and took the top job in December 2019. Under him, Dynavax supplied adjuvant for nearly a billion COVID-19 vaccine doses and, in December 2025, agreed to be acquired by Sanofi for roughly $2.2 billion.

Dr. Katelyn Jetelina is an epidemiologist, data scientist, and one of America's most influential science communicators. She founded Your Local Epidemiologist (YLE) in March 2020 as a few sentences to update her UT Health students about COVID-19 - and somehow that turned into a 365,000-subscriber newsletter reaching people in 133 countries with over 500 million total views. Named a TIME100 Most Influential Person in Health, she translates complex public health science into actionable insights twice a week, covering everything from vaccines and bird flu to gun violence and federal health policy. She holds a PhD in Epidemiology and Biostatistics, consults with the CDC, and serves as an adjunct professor at Yale School of Public Health - all while raising two daughters and having visited 50+ countries.

Katherine J. Wu, Ph.D. is a staff science writer at The Atlantic and one of the most respected science journalists working today. A former Harvard bacteriologist turned acclaimed writer, she translates complex biology - from pandemic viruses to the sex lives of deep-sea creatures - into stories that are simultaneously rigorous and riveting. Winner of the 2024 Kovler Prize and the 2022 Schmidt Award for Science Communication, she has reported for The New York Times, National Geographic, and Smithsonian, and holds a PhD in Microbiology and Immunobiology from Harvard. She writes the newsletter The Pivot, covering science and health.